A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Summary

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity

Timeline

Start

2024-10-01

Primary completion

2025-12-03

Completion

2025-12-03

Drugs

Indications